US 10,376,532 B2
Methods of treating, reducing the incidence of, and/or preventing ischemic events
Clive Arthur Arculus-Meanwell, Bernardsville, NJ (US); Simona Skerjanec, Basel (CH); and Jayne Prats, Carlisle, MA (US)
Assigned to Chiesi Farmaceutici, S.p.A., Parma (IT)
Filed by The Medicines Company, Parsippany, NJ (US)
Filed on Oct. 9, 2013, as Appl. No. 14/50,266.
Application 14/050,266 is a continuation in part of application No. 13/792,056, filed on Mar. 9, 2013, granted, now 9,427,448.
Application 13/792,056 is a continuation in part of application No. 12/943,717, filed on Nov. 10, 2010, granted, now 9,925,265.
Application 13/792,056 is a continuation in part of application No. 12/943,717, filed on Nov. 10, 2010, granted, now 9,925,265.
Claims priority of provisional application 61/260,361, filed on Nov. 11, 2009.
Prior Publication US 2014/0107032 A1, Apr. 17, 2014
Int. Cl. A61K 38/10 (2006.01); A61K 31/7076 (2006.01); A61K 31/4365 (2006.01); A61K 9/00 (2006.01); A61K 45/06 (2006.01); A61K 47/02 (2006.01); A61K 47/26 (2006.01); A61K 9/19 (2006.01)
CPC A61K 31/7076 (2013.01) [A61K 9/0019 (2013.01); A61K 9/19 (2013.01); A61K 31/4365 (2013.01); A61K 38/10 (2013.01); A61K 45/06 (2013.01); A61K 47/02 (2013.01); A61K 47/26 (2013.01)] 17 Claims
 
1. A method of treating or reducing the incidence of an ischemic event in a patient undergoing percutaneous coronary intervention (PCI), comprising concurrently administering to the patient a pharmaceutical composition comprising only one active composition, wherein the only one active composition consists essentially of cangrelor and a pharmaceutically acceptable excipient comprising one or more of the group consisting of mannitol and sorbitol, wherein the only one active composition is lyophilized; and a second pharmaceutical composition comprising only one other active ingredient wherein the only one other active ingredient consists essentially of bivalirudin.